Methods for treating humans having brain cancer
AssigneeNektar Therapeutics
InventorsMichael A. Eldon, Shibani S. Harite, Tamra L. Barker
Life of this patent
Estimating the term…
Abstract
Among other things, a method of treating a human having brain cancer is, the method comprising administering via a non-continuous dosing regimen to the human having brain cancer, a therapeutically effective amount of a pharmaceutical composition comprising a prodrug or a pharmaceutically acceptable salt thereof, wherein the non-continuous dosing regimen comprises administering the pharmaceutical composition no more frequently than once every seven days for at least two dosings.
Claims11
A method of treating a human having brain cancer, the method comprising administering via a non-continuous dosing regimen to the human having brain cancer, a therapeutically effective amount of a pharmaceutical composition comprising a prodrug of structure (I):
- or a pharmaceutically acceptable salt thereof, wherein the non-continuous dosing regimen comprises administering the pharmaceutical composition no more frequently than once every 21 days for at least two dosings in a dosage amount of irinotecan ranging from about 70 mg/m2 to about 300 mg/m2, to thereby maintain sustained therapeutic levels of greater than 0.5 ng/mL of SN-38 in plasma in the human for at least 21 days between dosings.
A method for achieving extended therapeutic efficacy of irinotecan, the method comprising
- administering to a human having brain cancer, a therapeutically effective amount of a pharmaceutical composition comprising a prodrug of structure (I):
- or a pharmaceutically acceptable salt thereof, wherein the administering comprises administering the composition at a frequency of between once every 21 days to once every 30 days for at least two dosings in a dosage amount of irinotecan ranging from about 70 mg/m2 to about 300 mg/m2, to thereby achieve for each of the at least two dosings an elimination half-life in plasma of SN-38 that exceeds 750 hours and greater than 0.5 ng/mL of SN-38 in plasma in the human for at least 21 days.
Dependencies are inferred from the claim text.